Filter
203
Filtered Results: 203
Text search:
vaccine
vial
monitor
Featured
Recommendations
34
New Publications
62
Language
Document type
No document type
91
Guidelines
58
Manuals
21
Studies & Reports
12
Fact sheets
9
Strategic & Response Plan
8
Training Material
2
Resource Platforms
1
Infographics
1
Countries / Regions
India
17
South Africa
10
Uganda
9
Kenya
8
Tanzania
6
Global
5
Philippines
4
Africa
4
Argentina
4
Ethiopia
4
Nepal
3
Rwanda
3
Nigeria
3
Zimbabwe
3
Latin America and the Carribbean
3
Sierra Leone
2
Senegal
2
Bangladesh
2
Zambia
2
Liberia
2
Myanmar / Burma
2
Cameroon
1
Syria
1
Burkina Faso
1
Afghanistan
1
Malawi
1
Guinea
1
Haiti
1
Cambodia
1
Guinea-Bissau
1
Congo, Democratic Republic of
1
West and Central Africa
1
Paraguay
1
United Kingdom
1
Brazil
1
Russia
1
Namibia
1
Yemen
1
Central African Republic
1
Mali
1
Libya
1
Botswana
1
South Sudan
1
Solomon Islands
1
Authors & Publishers
Publication Years
Category
Countries
83
Clinical Guidelines
35
Women & Child Health
17
Public Health
13
Key Resources
7
Capacity Building
4
Pharmacy & Technologies
2
Toolboxes
COVID-19
45
Pharmacy
17
Rapid Response
15
Polio
7
AMR
6
Ebola & Marburg
5
Caregiver
4
HIV
3
TB
3
NTDs
3
Cholera
2
NCDs
2
Conflict
2
Mental Health
1
Refugee
1
Natural Hazards
1
Planetary Health
1
Zika
1
Training on handling, storing and transporting Pfizer BioNTech COVID-19 Vaccine COMIRNATY® (Tozinameran)
recommended
4 August 2021. Currently, Pfizer BioNTech COVID-19 Vaccine COMIRNATY® (Tozinameran) is the only COVID-19 vaccine that should be stored and transported at -60ºC to -86ºC ultra-low temperature (ULT) conditions. Prior to use the vaccine can be transferred to -20ºC freezer or +2-8ºC refrigerator at...
Malaria vaccine: WHO position paper - March 2022
recommended
Weekly Epidemiological Record No 9, 2022, 97, 61–80
This position paper supersedes the 2016 publication, “Malaria vaccine: WHO position paper-2016.”1 It includes the updated WHO recommendations on the wider use of the RTS,S/AS01 vaccine for the reduction of malaria morbidity and mortality in ...
This is an e-learning module with the objective of providing education for health professionals and pregnant women using published results and studies based on COVID-19 surveillance data, which have indicated an increased risk among pregnant women of presenting with severe forms of COVID-19 and, the...
REG 174 INFORMATION FOR UK HEALTHCARE PROFESSIONALS
WHO Secretariat Information paper July 2016
The WHO Guide on Oral Cholera Vaccines in Mass Immunization Campaigns provides guidance on the planning and implementation of oral cholera vaccine (OCV) campaigns. It covers key aspects such as when and where to use OCVs, vaccine specifications, and recommendations for use in endemic areas, outbreak...
22 December 2020
The COVID-19 vaccine safety guidance manual has been developed upon recommendation and guidance of GACVS members, as well as by experts incorporating current and available information critical to all stakeholders when COVID-19 vaccines will be introduced.
For ease of use, the man...
Updated 28 December 2020
Rabies is fatal, vaccine-preventable disease responsible for an estimated 59,000 human deaths each year. Most cases are transmitted by dogs, and most deaths occur in underserved populations in Africa and Asia. Approximately 40% of deaths occur in children.
Smallpox eradication was certified in 1980. Mpox has been endemic in Central and West African countries since it was first detected in 1958 . It is a zoonosis; cases are often found close to tropical rainforests where various animals carry the orthopoxvirus that causes the disease. In endemic countr...
first issued 18 August 2022
Principles and Target Product Criteria. Roadmap January 12, 2015
This global guidance provided the framework for over 100 countries to develop their NDVPs. This updated (second) version supersedes the previous version published in 16 November 2020. New information has been added on the following areas:
the COVID-19 Partners Platform;
the use of COVID...
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenc...
nterim guidance, first issued 25 January 2021, updated 15 June 2021, updated 19 November 2021, updated 23 February 2022, updated 18 August 2022
These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
Th...
These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
fir...
Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac
These WHO interim recommendations for use of the Sinovac-CoronaVac were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been updat...
